Incident ESRD and treatment-resistant hypertension: the reasons for geographic and racial differences in stroke (REGARDS) study

Am J Kidney Dis. 2014 May;63(5):781-8. doi: 10.1053/j.ajkd.2013.11.016. Epub 2014 Jan 1.

Abstract

Background: Studies suggest that treatment-resistant hypertension is common and increasing in prevalence among US adults. Although hypertension is a risk factor for end-stage renal disease (ESRD), few data are available for the association between treatment-resistant hypertension and ESRD risk.

Study design: Prospective cohort study.

Setting & participants: We analyzed data from 9,974 REGARDS (Reasons for Geographic and Racial Differences in Stroke) Study participants treated for hypertension without ESRD at baseline.

Predictor: Treatment-resistant hypertension was defined as uncontrolled blood pressure (BP) with concurrent use of 3 antihypertensive medication classes including a diuretic or use of 4 or more antihypertensive medication classes including a diuretic regardless of BP.

Outcome: Incident ESRD was identified by linkage of REGARDS Study participants with the US Renal Data System.

Measurements: During a baseline in-home study visit, BP was measured twice and classes of antihypertensive medication being taken were determined by pill bottle inspection.

Results: During a median follow-up of 6.4 years, there were 152 incident cases of ESRD (110 ESRD cases among 2,147 with treatment-resistant hypertension and 42 ESRD cases among 7,827 without treatment-resistant hypertension). The incidence of ESRD per 1,000 person-years for hypertensive participants with and without treatment-resistant hypertension was 8.86 (95% CI, 7.35-10.68) and 0.88 (95% CI, 0.65-1.19), respectively. After multivariable adjustment, the HR for ESRD comparing hypertensive participants with versus without treatment-resistant hypertension was 6.32 (95% CI, 4.30-9.30). Of participants who developed incident ESRD during follow-up, 72% had treatment-resistant hypertension at baseline.

Limitations: BP, estimated glomerular filtration rate, and albuminuria assessed at a single time.

Conclusions: Individuals with treatment-resistant hypertension are at increased risk for ESRD. Appropriate clinical management strategies are needed to treat treatment-resistant hypertension in order to preserve kidney function in this high-risk group.

Keywords: Treatment-resistant hypertension; antihypertensive medication; end-stage renal disease; hypertension; kidney disease; kidney disease risk factor; renal failure; uncontrolled blood pressure.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Aged
  • Antihypertensive Agents / therapeutic use*
  • Blood Pressure*
  • Drug Resistance*
  • Female
  • Follow-Up Studies
  • Humans
  • Hypertension / complications
  • Hypertension / drug therapy*
  • Hypertension / ethnology
  • Incidence
  • Kidney Failure, Chronic / complications
  • Kidney Failure, Chronic / ethnology*
  • Kidney Failure, Chronic / physiopathology
  • Male
  • Middle Aged
  • Prevalence
  • Prospective Studies
  • Racial Groups*
  • Risk Factors
  • Stroke / ethnology*
  • Stroke / etiology
  • United States / epidemiology

Substances

  • Antihypertensive Agents